Don’t miss out the new IRDiRC publication developed by Therapies Scientific Committee (TSC) members Daniel O’Connor, Annemieke Aartsma-Rus, Anneliene Jonker, and Regulatory Scientific Committee (RSC) member, Michela Galbado – “Defining rare conditions in the era of personalized medicine“.
“Despite these consensus features, there is currently no common global agreement on the impact and widespread application of advances in molecular sciences and pathology on the definition of a rare condition”. The commentary article offers an insight on “the impact of defining rare conditions in the era of personalized medicine, including subsetting of common conditions, subsetting of rare conditions, individualized treatment options and shared molecular entity conditions”.
Read the full publication: here.